These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 9674458

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
    Allegra L, Konietzko N, Leophonte P, Hosie J, Pauwels R, Guyen JN, Petitpretz P.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():93-104. PubMed ID: 8737129
    [Abstract] [Full Text] [Related]

  • 4. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA, Unowsky J, Zhang H, Townsend L, Talbot GH.
    Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE, Cranfield R, Breisch S, Pettit R.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE, Zuck P, Vogel F, McIvor A, Peirzchala W, Smakal M, Staley H, Marr C.
    J Antimicrob Chemother; 1999 Oct; 44(4):515-23. PubMed ID: 10588313
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
    Henry D, Ellison W, Sullivan J, Mansfield DL, Magner DJ, Dorr MB, Talbot GH.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2262-6. PubMed ID: 9736546
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL.
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [Abstract] [Full Text] [Related]

  • 11. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
    Kemper P, Köhler D.
    Am J Med; 1992 Apr 06; 92(4A):98S-102S. PubMed ID: 1316079
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.
    Klietmann W, Cesana M, Rondel RK, Focht J.
    Antimicrob Agents Chemother; 1993 Nov 06; 37(11):2298-306. PubMed ID: 8285609
    [Abstract] [Full Text] [Related]

  • 13. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
    Dere WH, Farlow D, Therasse DG, Jacobson KD, Guerra FJ.
    Clin Ther; 1992 Nov 06; 14(2):166-77. PubMed ID: 1611641
    [Abstract] [Full Text] [Related]

  • 14. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M, Di Perna F, Boveri B, Di Marco F, Diamare F, Centanni S.
    J Chemother; 2000 Jun 06; 12(3):216-22. PubMed ID: 10877516
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA, Dorr MB, Magner DJ, Talbot GH.
    Clin Ther; 1999 Jan 06; 21(1):148-59. PubMed ID: 10090432
    [Abstract] [Full Text] [Related]

  • 17. Temafloxacin in acute purulent exacerbations of chronic bronchitis.
    Davies BI, Maesen FP, Gubbelmans HL, Cremers HM.
    J Antimicrob Chemother; 1990 Aug 06; 26(2):237-46. PubMed ID: 2120178
    [Abstract] [Full Text] [Related]

  • 18. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML, Jacobson KD, Guerra FJ, Therasse DG, Farlow D.
    Clin Ther; 1992 Aug 06; 14(2):214-29. PubMed ID: 1611645
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.